Walking Further with GLP-1RAs: Lessons from the STRIDE Trial

Abstract

Get full access to this article

View all access options for this article.

References

Verma

Leiter

Mangla

, et al. Epidemiology and burden of peripheral artery disease in people with type 2 diabetes: A systematic literature review. Diabetes Ther. 2024;15(9):1893-1961.

Beckman

Duncan

Damrauer

, et al. Microvascular disease, peripheral artery disease, and amputation. Circulation. 2019;140(6):449-458.

Fowkes

Aboyans

Fowkes

, et al. Peripheral artery disease: Epidemiology and global perspectives. Nat Rev Cardiol. 2017;14(3):156-170.

Criqui

Matsushita

Aboyans

, et al. Lower extremity peripheral artery disease: Contemporary epidemiology, management gaps, and future directions: A scientific statement from the American Heart Association. Circulation. 2021;144(9):e171-e191. doi:10.1161/CIR.0000000000001005

Mazzolai

Teixido-Tura

Lanzi

, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700.

Gornik

Aronow

Goodney

, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313-e1410. doi:10.1161/CIR.0000000000001251

Stevens

Simpson

Harnan

, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630-1638.

Kalantzi

Tentolouris

Melidonis

, et al. Efficacy and safety of adjunctive cilostazol to clopidogrel-treated diabetic patients with symptomatic lower extremity artery disease in the prevention of ischemic vascular events. J Am Heart Assoc. 2021;10(1):e018184.

Soga

Iida

Hirano

, et al. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79(4):541-548.

10.

Fassora

Calanca

Jaques

Mazzolai

Kayser

Lanzi

. Intensity-dependent effects of exercise therapy on walking performance and aerobic fitness in symptomatic patients with lower-extremity peripheral artery disease: A systematic review and meta-analysis. Vasc Med. 2022;27(2):158-170.

11.

Davies

Aroda

Collins

, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966.

12.

Sattar

Lee

MMY

Kristensen

, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.

13.

Perkovic

Tuttle

Rossing

, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121.

14.

Lincoff

Brown-Frandsen

Colhoun

, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.

15.

Nauck

Quast

Wefers

Meier

. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46(10):1102.

16.

Gouveri

Popovic

Papanas

. Potential new therapeutic implications of semaglutide: New colours of the rainbow? Diabetes Ther. 2024;15(1):13-18.

17.

Pantazopoulos

Gouveri

Papi

Papazoglou

Papanas

. GLP-1 receptor agonists, DPP-4 inhibitors and the skin-diabetes meets dermatology: A brief narrative review. Adv Ther. 2025;42(8):3621-3633.

18.

Mehdi

Pusapati

Anwar

, et al. Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209.

19.

Dhatariya

Bain

Buse

, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial. Diabetes Care. 2018;41(10):2229-2235.

20.

Brevetti

Giugliano

Brevetti

Hiatt

. Inflammation in peripheral artery disease. Circulation. 2010;122(18):1862-1875.

21.

Bonaca

Catarig

Houlind

, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): A phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580-1593.

22.

Karakasis

Patoulias

Fragakis

Mantzoros

. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113.

23.

Kang

Jung

. Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul). 2016;31(2):258-274.

24.

Marso

Daniels

Brown-Frandsen

, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.

25.

Rerkasem

Sripan

Pongtam

, et al. The prevalence and risk factors for peripheral arterial disease in adults living with human immunodeficiency virus. Int J Low Extrem Wounds. 2023;22(2):332-338.

26.

Rerkasem

Mangklabruks

Buranapin

, et al. Chronic kidney disease predicts adverse major cardiovascular events and adverse limb events in patients with diabetes and peripheral arterial disease. Int J Low Extrem Wounds. 2024;23(1):19-26.

27.

Rerkasem

Nopparatkailas

Nantakool

, et al The ability of clinical decision rules to detect peripheral arterial disease: A narrative review. Int J Low Extrem Wounds. 2025;24(2):273-282.